Scholar Rock Holding Corporation (SRRK)
Scholar Rock Holding Corporation (SRRK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Scholar Rock Holding Corporation (SRRK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Scholar Rock Holding Corporation (SRRK) Q4 2025 Earnings Call Transcript
Scholar Rock Holding Corporation (SRRK) Q4 2025 Earnings Call Transcript
Scholar Rock Chief Scientific Officer Conducts Multiple Sales Throughout January 2026
Mo Qatanani sold 14,898 shares directly for a transaction value of approximately $695,938 on Jan. 22, 2026, at a weighted average price of $46.71 per share. The sale represented 14.82% of Qatanani's direct holdings, reducing direct ownership to 85,660 shares, which equates to 0.08% of shares outstanding.
Scholar Rock Holding Corporation (SRRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Scholar Rock Holding Corporation (SRRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Scholar Rock: Apitegromab's Path Forward Remains Intact, Maintaining Buy Rating
I maintain a buy rating on Scholar Rock, raising my target price to $97, reflecting increased confidence in apitegromab's approval and commercial prospects. FDA setbacks are manufacturing-related, not clinical, with no new efficacy or safety concerns; remediation and a second CDMO are underway. Topline phase 3 data support apitegromab's novel mechanism and broad label potential, materially expanding SRRK's addressable market and pricing power.
Scholar Rock Holding Corporation (SRRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Scholar Rock Holding Corporation (SRRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Scholar Rock Holding Corporation (SRRK) Q3 2025 Earnings Call Transcript
Scholar Rock Holding Corporation ( SRRK ) Q3 2025 Earnings Call November 14, 2025 8:00 AM EST Company Participants Laura Ekas David Hallal - CEO & Chairman of the Board Akshay Vaishnaw - President of R&D, Member of Scientific Advisory Board and Director R. Keith Woods Vikas Sinha - Chief Financial Officer Conference Call Participants Mani Foroohar - Leerink Partners LLC, Research Division Eric Schmidt - Cantor Fitzgerald & Co., Research Division Tessa Romero - JPMorgan Chase & Co, Research Division Tazeen Ahmad - BofA Securities, Research Division Kripa Devarakonda Etzer Darout - Barclays Bank PLC, Research Division Marc Frahm - TD Cowen, Research Division Evan Seigerman - BMO Capital Markets Equity Research Presentation Operator Good morning, ladies and gentlemen, and welcome to Scholar Rock's Third Quarter 2025 Conference Call.
Scholar Rock: De-Risked Biotech, Playing The Approval Catalyst (Buy Rating)
Scholar Rock Holding Corporation (SRRK) is a clinical-stage biotech focused on targeted therapies for neuromuscular and fibrotic diseases, with Apitegromab as its lead asset. SRRK's Apitegromab achieved strong phase 3 results in spinal muscular atrophy, showing meaningful motor function gains and robust safety as an add-on therapy. The recent stock correction was due to manufacturing site issues, not clinical setbacks; approval is expected by 2026, presenting a speculative buy opportunity.
US FDA declines to approve Scholar Rock's muscle weakness drug
The U.S. Food and Drug Administration has declined to approve Scholar Rock's drug for a rare neuromuscular disease, citing issues at a third party manufacturing facility, the company said on Tuesday.
Scholar Rock Holding Corporation (SRRK) Q2 2025 Earnings Call Transcript
Scholar Rock Holding Corporation (NASDAQ:SRRK ) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants Akshay K. Vaishnaw - President of R&D, Member of Scientific Advisory Board and Director David L.
Scholar Rock Holding Corporation (SRRK) Q1 2025 Earnings Call Transcript
Scholar Rock Holding Corporation (NASDAQ:SRRK ) Q1 2025 Earnings Conference Call May 14, 2025 8:15 AM ET Company Participants Rushmie Nofsinger - VP, Corporate Affairs and IR David Hallal - CEO Akshay Vaishnaw - President of R&D Keith Woods - COO Vikas Sinha - CFO Conference Call Participants Allison Bratzel - Piper Sandler Michael Yee - Jefferies Tessa Romero - JPMorgan David Nierengarten - Wedbush Gary Nachman - Raymond James Kripa Devarakonda - Truist Marc Frahm - TD Cowen Andres Maldonado - H.C. Wainwright Dennis Kennedy - LifeSci Capital Operator Ladies and gentlemen, thank you for standing by.
Why Scholar Rock Stock Took a Knock on Monday
Although there are many examples throughout history of positive changes in top company management teams, important personnel moves tend to unsettle investors. They get worried that significant changes could reflect instability, indecision, or both in a company's decision-making.
